Exiqon Posts 15 Percent Revenue Increase for Q2 | GenomeWeb

NEW YORK (Genomeweb News) – Exiqon announced today that its second quarter revenues increased 15 percent year over year as it significantly trimmed its net loss for the period.

The Danish firm brought in total revenues of DKK 33.3 million ($5.97 million) for the second quarter, up from DKK 29.1 million for Q2 2012. Exiqon said that its research product sales and services revenue was up 21 percent to DKK 26.8 million from DKK 22.2 million.

The firm cut its net loss to DKK 1.3 million, or DKK .03 per share, from DKK 4.1 million, or DKK .12 per share, year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.